title: [Safety and efficacy of LK565--a new polymer ultrasound contrast medium].
abstract: We tested a newly developed ultrasound contrast agent (LK565) from poly-aspartic acid (PAA; particle size 3 microns; particle content: air) in 15 healthy male probands (20-38 years) in doses of 10, 30 and 100 mg intravenously. One day and immediately before the study a routine laboratory test, an ECG and an EEG were performed. The EEG was continued through the complete time period that the ultrasound contrast lasted, i.e., up to one hour after the injection. All probands were followed clinically for 24 hours when the routine laboratory and the ECG were repeated. All subjects tolerated the contrast agent well. There were no changes in either the EEG or in the ECGs performed throughout the study. There were no significant laboratory changes except for a small and transient increase in the neutrophil count in five probands receiving the highest dose. All injections with 10 mg led to a significant improvement in the color Doppler signal. All injections with 30 and 100 mg led to a very strong echo contrast lasting for 5 to 12 minutes in the harmonic B-mode. Using the latter, fragments of intramyocardial coronaries could be visualized. The tested ultrasound polymer contrast agent was safe, well tolerated and efficient in this acute study.
authors.affiliation: Klinik für Innere Medizin/Kardiologie Universität Leipzig Herzzentrum Russenstr. 19 04289 Leipzig, Germany. rainer.zotz@t-online.de
authors.forename: R J
authors.initials: RJ
authors.lastname: Zotz
authors.forename: S
authors.initials: S
authors.lastname: Schenk
authors.forename: A
authors.initials: A
authors.lastname: Kuhn
authors.forename: S
authors.initials: S
authors.lastname: Schlünken
authors.forename: V
authors.initials: V
authors.lastname: Krone
authors.forename: W
authors.initials: W
authors.lastname: Bruns
authors.forename: S
authors.initials: S
authors.lastname: Genth
authors.forename: G
authors.initials: G
authors.lastname: Schuler
mesh_terms: D000328:Adult; D003287:Contrast Media / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004452:Echocardiography; D004562:Electrocardiography / Q000187:drug effects; D004569:Electroencephalography / Q000187:drug effects; D005989:Glycerides; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010455:Peptides / Q000009:adverse effects
chemical_list: D003287:Contrast Media; D005989:Glycerides; D010455:Peptides; C017645:polyaspartate; C017974:methyl-p-myristyloxycinnamic acid 1-monoglyceride